Xencor, Inc. (XNCR)
22.85
-1.15
(-4.79%)
USD |
NASDAQ |
Oct 16, 16:00
22.87
+0.02
(+0.09%)
After-Hours: 20:00
Xencor Research and Development Expense (Annual) : 239.43M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 239.43M |
| December 31, 2024 | 227.69M |
| December 31, 2023 | 253.60M |
| December 31, 2022 | 199.56M |
| December 31, 2021 | 192.51M |
| December 31, 2020 | 169.80M |
| December 31, 2019 | 118.59M |
| December 31, 2018 | 97.50M |
| Date | Value |
|---|---|
| December 31, 2017 | 71.77M |
| December 31, 2016 | 51.87M |
| December 31, 2015 | 34.14M |
| December 31, 2014 | 18.52M |
| December 31, 2013 | 17.00M |
| December 31, 2012 | 12.67M |
| December 31, 2011 | 12.66M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 93.26M |
| UroGen Pharma Ltd. | 67.11M |
| MeiraGTx Holdings Plc | 129.32M |
| IDEAYA Biosciences, Inc. | 314.70M |
| Iovance Biotherapeutics, Inc. | 300.27M |